Cabg Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Coronary artery bypass graft (CABG) surgery is the most common cardiac surgical procedure worldwide, performed in approximately 200,000 patients annually in the United States and over 500,000 globally per year. The operation establishes new routes for blood flow to the myocardium by connecting conduits — harvested arterial or venous grafts — from the aorta (or a parent artery) to the coronary arteries downstream of obstructive atherosclerotic plaques. By bypassing stenosed coronary segments, CABG restores adequate myocardial perfusion, relieves angina, prevents myocardial infarction, and prolongs survival in patients with severe coronary artery disease (CAD).

CABG is performed via a median sternotomy (midline sternal incision) providing access to the heart and great vessels. The standard approach uses cardiopulmonary bypass (CPB — the heart-lung machine) which oxygenates and circulates blood during the period of cardioplegic cardiac arrest required to sew precise graft anastomoses onto the coronary arteries. The preferred conduit for the left anterior descending (LAD) artery — the most important coronary vessel — is the left internal mammary artery (LIMA, also called the left internal thoracic artery, LITA), which is harvested from the inside of the left chest wall. The LIMA-to-LAD graft has a 10-year patency of approximately 95%, dramatically better than saphenous vein grafts (SVG — harvested from the leg), which have a 10-year patency of only 50–60%.

Total arterial revascularisation — using the LIMA plus the right internal mammary artery (RIMA), the radial artery from the non-dominant forearm, and/or the gastroepiploic artery — maximises long-term graft patency. The BIMA (bilateral internal mammary artery) strategy has been shown in the ART trial and multiple observational studies to improve long-term survival compared to single IMA strategies, though wound healing complications (sternal wound infection in diabetic patients) require careful patient selection. Modern CABG is a safe, predictable operation with a 30-day mortality below 1.5% at high-volume centres for elective isolated coronary bypass.

CABG is most strongly indicated for three-vessel coronary artery disease (disease in all three major epicardial coronary territories — LAD, circumflex, right coronary artery), left main coronary artery (LMCA) stenosis, and multivessel disease in diabetic patients or patients with significantly reduced left ventricular function (ejection fraction below 35%). The landmark SYNTAX trial demonstrated that patients with complex three-vessel or left main disease (SYNTAX score above 22–23) have significantly better outcomes with CABG than percutaneous coronary intervention (PCI) in terms of major adverse cardiac and cerebrovascular events at 5 years, primarily driven by lower rates of repeat revascularisation.

For diabetic patients with multivessel CAD, the FREEDOM trial definitively established CABG superiority over PCI — CABG reduced the composite of death, nonfatal MI, and stroke significantly at 5 years in insulin-treated and non-insulin-treated diabetics, due to both more complete revascularisation and the superior long-term patency of arterial grafts compared to drug-eluting stents in the setting of accelerated and diffuse atherosclerosis characteristic of diabetes. CABG is also the preferred revascularisation strategy for patients who require concurrent cardiac surgery (valve repair/replacement, left ventricular aneurysm resection, or aortic root surgery), allowing a single-operation complete cardiac repair.

Patients undergo comprehensive pre-operative assessment including coronary angiography (defining coronary anatomy and stenosis severity), left ventricular function assessment by echocardiography or cardiac MRI, surgical risk scoring (Society of Thoracic Surgeons STS score, or EuroSCORE II), respiratory function testing, carotid duplex ultrasound in patients above 65 years or with neurological history, and assessment of conduit availability (saphenous vein assessment by duplex ultrasound, radial artery Allen's test). Heart team review — multidisciplinary discussion involving interventional cardiologists, cardiac surgeons, imaging specialists, and anaesthetists — is mandatory for guiding the decision between CABG, PCI, and hybrid approaches.

CABG is contraindicated in patients with diffuse coronary disease without suitable distal vessels for grafting (rare, typically end-stage coronary disease), active infection, and patients with limited life expectancy from non-cardiac causes. High-risk but not inoperable patients (advanced age, poor LV function, previous sternotomy, severe comorbidities) require careful risk-benefit discussion. Off-pump CABG (OPCAB) — performed on the beating heart without cardiopulmonary bypass — may be preferred in patients at high CPB risk (severe aortic atherosclerosis, poor renal function, prior stroke, severe carotid disease), avoiding the systemic inflammatory response and microembolic risks of CPB.

Conventional on-pump CABG with cardiopulmonary bypass remains the dominant technique, offering optimal operating conditions for precise anastomosis construction. The heart is arrested with cold cardioplegia solution (potassium-rich, protecting against ischaemia) while the bypass machine maintains systemic circulation. Anastomoses are performed with fine polypropylene (Prolene) sutures under loupe magnification.

Off-pump CABG (OPCAB) performs anastomoses on the beating, perfused heart using mechanical stabilising devices (Octopus, Medtronic) that immobilise the local epicardial region around each target vessel. The ROOBY, CORONARY, and GOPCABE randomised trials showed no significant mortality difference between on-pump and off-pump CABG in overall populations; a meta-analysis suggests OPCAB may reduce stroke and AF rates while carrying a slightly higher risk of graft occlusion. In experienced hands, OPCAB achieves excellent results equivalent to on-pump.

Minimally invasive direct coronary artery bypass (MIDCAB) — through a small left thoracotomy — and robotic-assisted CABG (TotallyEndoscopicCABG, TECAB) offer smaller incisions for selected patients requiring isolated LAD revascularisation via LIMA-to-LAD, avoiding sternotomy. Hybrid revascularisation — LIMA-to-LAD via MIDCAB combined with PCI for non-LAD lesions — is an emerging strategy for patients in whom full surgical multivessel CABG carries excessive risk, preserving the benefits of the LIMA-to-LAD graft while treating other vessels percutaneously. Off-pump CABG (beating-heart surgery) avoids cardiopulmonary bypass in selected patients, potentially reducing systemic inflammation, renal injury, and neurocognitive complications, though conduit management requires specialised technique. When conventional CABG carries excessive risk, preserving the benefits of the LIMA-to-LAD graft while treating other vessels percutaneously is the hybrid strategy.

CABG provides complete revascularisation of all significantly diseased coronary territories, achieving relief of angina in over 90% of patients and substantially prolonging event-free survival in appropriately selected patients. A landmark meta-analysis (Yusuf et al., 1994, Lancet) of 10 randomised trials comparing CABG versus medical therapy showed a survival benefit for CABG in high-risk patients (three-vessel disease, LMCA disease, impaired LV function) persisting to 10 years. The SYNTAX trial's 10-year follow-up confirmed continued CABG superiority over PCI for complex three-vessel disease.

For patients with left ventricular dysfunction (ejection fraction below 35%), CABG improves LV function by revascularising hibernating myocardium — myocardium that is chronically ischaemic but viable, exhibiting systolic dysfunction that reverses with restoration of blood supply. The STICH trial demonstrated that CABG plus optimal medical therapy significantly reduces cardiovascular hospitalisation and all-cause mortality compared to medical therapy alone in patients with severe ischaemic cardiomyopathy, with benefits persisting over 10 years of follow-up. Graft patency is the key determinant of long-term outcome — total arterial revascularisation strategies with BIMA grafting have shown 10-year mortality reductions of 2–4% compared to single IMA strategies in propensity-matched analyses.

The 30-day mortality for isolated elective CABG is below 1.5% at high-volume centres (STS-reported risk), with higher rates for combined CABG-valve procedures (2–5%), emergency CABG, redo sternotomy, and cases with severely depressed LV function or haemodynamic compromise. Stroke — the most feared neurological complication — occurs in 1–2% of elective CABG patients, predominantly from embolisation of aortic atheromatous debris (particularly during aortic cannulation, cross-clamping, and clamp release) or from AF-related thromboemboli. Epiaortic ultrasound intraoperatively guides avoidance of heavily diseased aortic segments.

Peri-operative myocardial infarction (new wall motion abnormality or enzyme rise indicating graft occlusion or inadequate myocardial protection) occurs in 2–3% of cases. Deep sternal wound infection (mediastinitis) — more common in bilateral IMA harvest, especially in obese diabetics — occurs in 1–3% and can be life-threatening, requiring surgical debridement, VAC (vacuum-assisted closure) therapy, and often flap reconstruction. Post-operative atrial fibrillation (POAF) occurs in 20–30% of patients after cardiac surgery (peak on day 2), associated with prolonged hospital stay and increased stroke risk, managed with rate control, anticoagulation, and cardioversion. Renal failure requiring temporary dialysis occurs in 1–5% depending on pre-operative renal function. Saphenous vein harvest site complications (wound infection, lymphocoele, numbness) affect up to 10% of patients.

After CABG, patients typically spend 2–3 days in the cardiac ICU and 4–5 days on a surgical ward, with total hospital stay of 7–10 days for uncomplicated cases. Full physical recovery requires 6–12 weeks, with sternal healing taking 6–8 weeks. Driving is restricted for 4–6 weeks post-sternotomy. Cardiac rehabilitation — a structured programme of supervised exercise, education, and risk factor management — is strongly recommended from approximately 6 weeks post-operatively, reducing mortality by 20–26% at 5 years per Cochrane meta-analysis data.

Post-operative medications invariably include aspirin (75–100 mg lifelong for SVG patency — although ticagrelor dual antiplatelet therapy for 1 year has shown improved graft patency in the DACAB trial), statin (high-intensity lifelong), ACE inhibitor or ARB, beta-blocker, and proton pump inhibitor cover for aspirin. Coronary CT angiography or nuclear perfusion imaging is performed if recurrent symptoms suggest graft failure. Graft occlusion requiring PCI (grafting stenosis or body stenosis) is managed percutaneously in most cases. Repeat CABG (redo sternotomy) carries significantly higher risk than primary CABG and is deferred as long as possible by aggressive medical therapy and staged PCI to grafts.

In the United States, CABG costs $100,000–$250,000 for elective isolated bypass, including surgeon fees, ICU, ward stay, anaesthesia, implants, and rehabilitation. Combined CABG-valve procedures cost $150,000–$350,000. These figures are primarily borne by Medicare, Medicaid, or private insurance in the US; uninsured patients face catastrophic out-of-pocket expenses.

India is the world leader in high-quality affordable cardiac surgery for international patients. CABG at JCI-accredited centres such as Narayana Hrudayalaya, Apollo Hospitals, Fortis Escorts Heart Institute, and Medanta Medicity costs $5,000–$10,000 all-inclusive (surgeon, anaesthesia, ICU, 8–10 day hospital stay, medications, 6-week follow-up). Indian cardiac surgical outcomes data — particularly from Narayana Hrudayalaya, which performs over 15,000 cardiac surgeries annually — are comparable to international benchmarks, with CABG 30-day mortality consistently below 2%. Thailand offers CABG at $12,000–$22,000; Singapore at $20,000–$35,000. The savings represent 80–90% versus US costs, while receiving world-class surgical care. Medical tourists typically spend 3–4 weeks in India, covering the operation and initial post-operative recovery before returning home.

Percutaneous coronary intervention (PCI) with drug-eluting stents is the primary alternative to CABG for coronary revascularisation, offering a less invasive approach with faster recovery. PCI is preferred over CABG for single-vessel disease, two-vessel disease without LAD involvement, and for patients at high surgical risk. However, for the anatomical profiles that most benefit from CABG (three-vessel disease, LMCA disease, multivessel disease in diabetics, LV dysfunction), PCI results in significantly more frequent repeat revascularisation and, in some subgroups, higher cardiovascular mortality. The choice is made through Heart Team review considering coronary anatomy complexity (SYNTAX score), patient preference, surgical risk, and institutional expertise.

Optimal medical therapy (OMT) alone — comprising high-intensity statins, dual antiplatelet therapy, ACE inhibitor, beta-blocker, and lifestyle modification — is appropriate for patients with stable CAD and low-intermediate coronary complexity (ISCHEMIA trial: no difference in primary outcome between revascularisation and OMT in patients without LMCA disease and EF above 35% at 5 years), though it is not appropriate for the high-risk coronary anatomy subsets that benefit most from CABG. Transmyocardial laser revascularisation (TMR) — creating laser channels in the myocardium to stimulate angiogenesis — is a palliative procedure for refractory angina in patients not suitable for CABG or PCI, associated with reduction in angina class but no demonstrated mortality benefit.